Alaska Hematology Oncology Conference

Anchorage, AK US
May 11, 2024

The Alaska Hematology Oncology Conference is an accredited continuous education to improve the care of cancer patients by educating cancer care providers about precision-guided management in hematology and oncology. Regional and national experts in the field will share comprehensive insights into the actionable molecular variations seen in common cancers. The event's format is tailored to promote active learning, enhance knowledge retention, and encourage practitioners to apply fresh insights into their clinical routines. Through didactics, case-centric discussions, and lively Q&A sessions, attendees can gain clarity, address uncertainties, and interact with hematology and oncology experts. This conference aims to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in precision-guided management in hematology and oncology.  It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Hematologists/ Oncologists
  • Oncology Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses
  • Researchers and others

ORGANIZING COMMITTEE

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Co- Chairs:

Joseph Rosales, MD- Virginia Mason Franciscan Health

Anusiyanthan Mariampillai, MD-  Alaska Native Tribal Health Consortium

 

VENUE INFORMATION

A limited number of rooms have been booked at The Lakefront Anchorage at a discounted nightly rate of $249 per room for this conference's attendees and sponsors. Please book your room at the link here by Sunday, March 31, 2023, to receive the discounted group rate. 

Learning Objectives

  1. Review common molecular abnormalities in various cancers and the optimal timing to test for these abnormalities.
  2. Interpret the findings from next-generation sequencing and other biomarkers that indicate the likelihood of response to specific therapies while also understanding the inherent challenges.
  3. Apply optimal strategies centered on molecular-targeted treatments in the management of patients with cancer.
  4. Summarize emerging research, the mechanism of action, and the significance of new molecular-targeted treatments in managing cancer patients.

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Course opens: 
11/22/2023
Course expires: 
08/08/2024
Event starts: 
05/11/2024 - 8:00am PDT
Event ends: 
05/11/2024 - 4:30pm PDT
Cost:
$150.00

MAY 11, 2024

All times are listed in Alaska Time (AKT)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome Remarks 

08:05 AM – 08:20 AM  Addressing Global Cancer Health Disparities - Building a 200-Bed Cancer Hospital In Nepal - Justin Marquart


08:20 AM – 09:50 AM  Session 1: Women’s Cancers 

Moderator: Anu Mariampillai, MD

08:20 AM – 08:50 AM  Non-Metastatic Breast Cancer - Recent Advances - Bora Lim, MD

08:50 AM – 09:20 AM  Management of Metastatic Breast Cancer in 2024 - Meaghan O'Malley, MD

09:20 AM – 09:50 AM  Advances in Management of Ovarian Cancer - Dan Veljovich, MD


09:50 AM – 10:00 AM  Break & Exhibits


10:00 AM – 12:00 PM  Session 2: General Oncology

Moderator: Joseph Rosales, MD

10:00 AM – 10:30 AM  Biomarker-Guided Treatment of Advanced Non-Small Cell Lung Cancer - Rafael Santana-Davila, MD

10:30 AM – 11:00 AM  Advances in the Management of Advanced Prostate Cancer - Julie Graff, MD

11:00 AM – 11:30 AM  Management of Immunotherapy Toxicities - Shailender Bhatia, MD

11:30 AM – 12:00 PM  Panel Discussion


12:00 PM – 01:00 PM  Lunch & Exhibits


01:00 PM – 02:30 PM  Session 3: GI Oncology 

Moderator: Anu Mariampillai, MD

01:00 PM – 01:30 PM  Advances in the Management of Colorectal Cancer - Ronan Hsieh, MD

01:30 PM – 02:00 PM  Updates in the Management of Gastric and GE junction Cancers - Bruce Lin, MD

02:00 PM – 02:30 PM  Panel Discussion 


02:30 PM – 03:00 PM  Break & Exhibits


03:00 PM – 04:00 PM  Session 4: Hematologic malignancies

Moderator: Joseph Rosales, MD

03:00 PM – 03:30 PM  Recent Updates in Management of Diffuse Large B cell Lymphoma - David Aboulafia, MD

03:30 PM – 04:00 PM  Multiple Myeloma - Swathi Namburi, MD


04:00 PM – 04:05 PM: Adjourn

The Lakefront Anchorage
4800 Spenard Rd
Suite 200
Anchorage, AK 99517
United States

A limited number of rooms have been booked at The Lakefront Anchorage at a discounted nightly rate of $249 per room for this conference's attendees and sponsors. Please book your room at the link here by Sunday, March 31, 2023, to receive the discounted group rate. 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Anusiyanthan Mariampillai, MD

has no relevant financial relationships to disclose at this time.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Amphivena;.
has a financial relationship (Grant Or Contract) with Exicure;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Grant Or Contract) with 4SC;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with Kuni Foundation;.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.

Julie Graff, MD

has no relevant financial relationships to disclose at this time.

Ronan Hsieh, MD, MS

has no relevant financial relationships to disclose at this time.

Bora Lim, M.D.

has a financial relationship (Professional Services) with Gilead;.

Bruce Lin, Medical Oncologist

has no relevant financial relationships to disclose at this time.

Swathi Namburi, MD

has no relevant financial relationships to disclose at this time.

Meaghan O'Malley

has no relevant financial relationships to disclose at this time.

Rafael Santana-Davila, MD

has a financial relationship (Grant Or Contract) with Astellas Pharma;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Aztra-Zeneca;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Monte Rosa Therapeutics;.
has a financial relationship (Professional Services) with Mirati Therapeutics;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Alpine Immune Sciences;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Grant Or Contract) with Isa Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Jounce Therapeutics;.
has a financial relationship (Professional Services) with Catalyst Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Beyond Spring Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with ALX Oncology ;.

Dan Veljovich, MD

has a financial relationship (Stock) with VEEV Veeva Systems;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Stock) with ABBV Abbvie;.
has a financial relationship (Stock) with GILD GIlead;.
has a financial relationship (Stock) with JNJ Johnson and JOhnson;.
has a financial relationship (Stock) with PFE Pfizer;.
has a financial relationship (Stock) with UNH United Health;.
has a financial relationship (Independent contractor) with GSK;.
has a financial relationship (Stock) with ADPT Adaptive BIotech;.
has a financial relationship (Stock) with DOCS DOximity;.
has a financial relationship (Stock) with ISRG Intuitive surgical;.
has a financial relationship (Stock) with NVTA Invitae;.
has a financial relationship (Stock) with TDOC Teladoc;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Stock) with CVS CVS Health;.
has a financial relationship (Stock) with HLN Haleon PLC;.
has a financial relationship (Stock) with MRNA Moderna;.
has a financial relationship (Stock) with SGEN Seattle Genetics;.
has a financial relationship (Independent contractor) with Eisai;.
has a financial relationship (Stock) with AZN AstraZeneca;.
has a financial relationship (Stock) with GSK;.
has a financial relationship (Stock) with MRK Merck;.

Available Credit

  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme .

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.